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Testosterone boosts physical 
activity in male mice via 
dopaminergic pathways
Ferran Jardí1, Michaël R. Laurent2,3, Nari Kim1, Rougin Khalil1, Dimitri De Bundel4, Ann Van 
Eeckhaut4, Lawrence Van Helleputte5, Ludo Deboel1, Vanessa Dubois2,7, Dieter Schollaert1, 
Brigitte Decallonne1, Geert Carmeliet  1, Ludo Van den Bosch5, Rudi D’Hooge6, Frank 
Claessens  2 & Dirk Vanderschueren1
Low testosterone (T) in men, especially its free fraction, has been associated with loss of energy. In 
accordance, orchidectomy (ORX) in rodents results in decreased physical activity. Still, the mechanisms 
through which T stimulates activity remain mostly obscure. Here, we studied voluntary wheel running 
behavior in three different mouse models of androgen deficiency: ORX, androgen receptor (AR) knock-
out (ARKO) and sex hormone binding globulin (SHBG)-transgenic mice, a novel mouse model of “low 
free T”. Our results clearly show a fast and dramatic action of T stimulating wheel running, which is 
not explained by its action on muscle, as evidenced by neuromuscular studies and in a muscle-specific 
conditional ARKO mouse model. The action of T occurs via its free fraction, as shown by the results in 
SHBG-transgenic mice, and it implies both androgenic and estrogenic pathways. Both gene expression 
and functional studies indicate that T modulates the in vivo sensitivity to dopamine (DA) agonists. 
Furthermore, the restoration of wheel running by T is inhibited by treatment with DA antagonists. 
These findings reveal that the free fraction of T, both via AR and indirectly through aromatization into 
estrogens, stimulates physical activity behavior in male mice by acting on central DA pathways.
Physical inactivity has emerged as a global epidemic. Less than 50% of the adult Western population meets the 
minimum levels of recommended moderate-to-vigorous exercise, whilst spending 60% of their time in sedentary 
pursuits1,2. The lack of regular exercise is estimated to cause 6% of the burden of disease from coronary heart dis-
ease, 7% of type 2 diabetes and 10% of both breast and colon cancer3, and accounts for 1.5–3.0% of direct health-
care costs4. It is of no surprise, therefore, that implementing regular exercise on a population level has become a 
key priority in public health policy.
Over the past several years, new insights have revealed the existence of a neurophysiological basis regulating 
the motivation to engage in regular physical exercise. Locomotion is a well-established sexually dimorphic behav-
ior in rodents5 that responds to androgens and estrogens6,7. Diminished self-reported physical activity was asso-
ciated to low testosterone (T) levels in a cohort of 1954 German men8. Still, the association between sex steroids 
and physical activity in humans, as assessed by objective measures, has not been studied so far.
With ageing, serum total T concentrations gradually decrease in men9. In parallel, there is an increase in the 
concentrations of sex hormone-binding globulin (SHBG)9, a high-affinity binding protein for androgens and 
estrogens. This results in a more pronounced reduction of bioavailable or free T levels as men age9. We recently 
showed that free T concentrations correlated better than total T with androgen deficiency–related symptoms 
and signs in men with late-onset hypogonadism10. Despite controversy surrounding the diagnostic criteria and 
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treatment of so-called late-onset male hypogonadism, sales of prescription T replacement drugs in US topped 
$1.8 billion in 201111. Androgen replacement in elderly men with sarcopenia and low T has been reported to 
increase muscle strength in several, but not all, clinical trials12,13. T therapy in elderly men remains controversial 
because of the potential side effects on the cardiovascular system and prostate14. Given this background, the pos-
itive impact of T stimulating physical activity and the underlying mechanisms of action represent an additional 
consideration for T replacement in elderly, mobility-impaired, frail or sarcopenic elderly men.
Animal models represent an indispensable tool to understand how T influences locomotor behavior. Both 
orchidectomy (ORX) and knock out (KO) of the androgen receptor (AR) in mice replicate several behavioral 
features of sex steroid deficiency in humans15. Wheel running is a rewarding behavior observed even in wild 
rodents and other animals16. In mice, we and others have reported an almost complete abrogation of wheel run-
ning activity after ORX and in ARKO17,18. However, a neuromuscular dysfunction resulting from the loss of 
androgenic stimulation could alternately explain the low wheel running phenotype in ORX and ARKO mice. The 
anabolic effects of androgens on muscle mass are well-documented in men, although in mice limb muscle appear 
less androgen-sensitive19. Thus, the contribution of the central (motivation) over the peripheral (neuromuscular) 
actions of androgens on activity needs to be elucidated.
Another open issue regarding the actions of T on physical activity behavior is the role for free T. By using a 
transgenic (Tg) mouse model expressing human SHBG20, we recently demonstrated that T is “trapped” in the 
circulation by SHBG and cannot enter into target tissues to elicit its physiological functions21. The androgen defi-
ciency phenotype in SHBG-Tg mice was however attenuated compared to ORX21. Therefore, the SHBG mouse 
model represents a unique approach to study the impact of free T whilst replicating better than other “complete” 
androgen deficiency models the moderate drop in the T levels as they occur in ageing men.
T can directly, or indirectly, following conversion to dihydrotestosterone (DHT), act via the androgen receptor 
(AR). T, but not DHT, can also be converted into 17β-estradiol (E2) by the aromatase enzyme and activate estro-
gen receptors (ERs). Aromatization is an important determinant of many of the actions of T22. In male mice, the 
circulating levels of E2 are negligible21 and local aromatization of T within different tissues including the brain is 
believed to constitute a key mechanism of estrogenic action. For instance, T acts predominantly as a prohormone 
for E2 in the programming of male-typical and territorial behavior in mice, although execution of this behavior 
relies on the AR23. It remains debated whether this dual androgenic and estrogenic action of T also applies to 
wheel running. A couple of studies in mice have indicated such a dual mode of action of T on promoting wheel 
running6,7, although this hypothesis could not be proven by other authors24.
Although it is clear that sex steroids are important neuroendocrine regulators of physical activity behavior, 
the underlying mechanisms remain poorly understood. The brain dopamine (DA) system is suggested as the final 
common pathway for a complex network of neuromediators contributing to the modulation of physical activity. 
In particular, the activation of DA receptor 1(DR1)- and DR2-neurons in the striatum exerts a selective control 
over locomotion25. Despite evidence indicating a role for T in DA synthesis, release and metabolism, results are 
mostly inconsistent between studies26. Therefore, further studies are warranted to better understand the neuroen-
docrine interaction between androgens and the central DA system.
The aim of this study was to examine how T regulates voluntary physical activity. In particular, our goal 
was to answer the four following questions: (1) does T-induced stimulation of activity depend in part on its 
aromatization into E2? (2) is the free fraction of T mediating the actions on activity? (3) to what extent are the 
effects of androgens exerted through central mechanisms (motivation) independent from peripheral (neuromus-
cular) actions? and (4) are the brain DA pathways implicated in the T regulation of activity? For this purpose, we 
explored wheel running, home-cage activity and the neuromuscular function in two mouse models of androgen 
deficiency (ORX and ARKO) given placebo, T or dihydrotestosterone (DHT) replacement, as well as in SHBG-Tg 
mice. The implication of the DA system in the T-mediated regulation of physical activity was determined in vivo 
by monoamine profiling, gene expression studies and pharmacological challenging with dopaminergic drugs.
Results
Testosterone is more effective than dihydrotestosterone in restoring wheel running in ORX 
mice. When C57BL/6J sham mice were given free access to a running wheel, they steadily increased their 
activity each day until they reached a plateau at 2 weeks (Fig. 1A). As expected, orchidectomy (ORX) com-
pletely abrogated the progressive increase in the daily running distance [androgens: F(3,29) = 9.252, P = 0.0002; 
time: F(18,522) = 32.11, P < 0.0001; interaction: F(54,522) = 7.345, P < 0.0001; Fig. 1A]. Supplementation with 
T induced an almost 250% increase in the activity levels during the plateau phase compared to ORX (ORX: 
1.09 ± 0.18 km; ORX + T: 3.8 ± 0.57 km; P < 0.001; Fig. 1B), restoring wheel running almost to sham levels 
(P > 0.05 vs. sham). DHT also augmented the running distance in ORX animals (Fig. 1A and B) but to a lesser 
extent, not reaching statistical significance. Indeed, Bonferroni post hoc analysis revealed that DHT-treated mice 
significantly ran less compared to sham animals (sham: 5.49 ± 0.51 km; ORX + DHT: 2.31 ± 0.31 km; P < 0.001; 
Fig. 1B). Still, treatment with the AR antagonist enzalutamide diminished wheel running activity by 40% in 
ORX + T but not ORX mice [T: F(1,10) = 7.140, P < 0.05; enzalutamide: F(2,20) = 7.532, P < 0.01; interaction: 
F(2,20) = 5.307, P = 0.0142; Fig. 1C].
Similar but attenuated effects for ORX and hormone replacement were observed in home-cage activity, which 
was reduced by ORX and restored by T as well as DHT (Fig. 1D and E). When evaluating the peak of ambu-
latory activity during dark hours, sham animals were found to be more active than ORX (sham: 9005 ± 1355 
beam counts; ORX: 4457 ± 455 beam counts; P < 0.05; Fig. 1E). No differences were observed between sham and 
ORX + T- or DHT-treated mice (Fig. 1E).
The effectiveness of ORX, hormone replacement and treatment with enzalutamide was demonstrated by 
determining the weight of the androgen-sensitive seminal vesicle and levator ani/bulbocavernosus (LA/BC) 
muscle complex (Fig. 1F).
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SHBG inhibits the stimulatory effects of testosterone on wheel running activity. To deter-
mine the contribution of free T to the actions of T we assessed wheel running after ORX and T replacement in 
both sex hormone-binding globulin (SHBG)-Tg and wild type (WT) littermate controls. SHBG-Tg mice did 
not display the progressive increase in the daily running distance as observed in their WT littermates [geno-
type: F(1,10) = 7.806, P = 0.0190; time: F(18,180) = 4.325, P < 0.0001; interaction: F(18,180) = 5.451, P < 0.0001; 
Fig. 2A]. Expression of SHBG reduced the activity levels by 56% during the plateau phase (P ≤ 0.01; Fig. 2B). As 
previously described21, SHBG-Tg mice showed a mild hypogonadism, confirmed by a 34% and a 56% decrease in 
the weight LA/BC muscles and seminal vesicles, respectively (P < 0.0001 vs. WT; Fig. 2C). In a similar pattern, we 
observed a 57% reduction in the concentration of E2 in the brain of SHBG-Tg mice (P < 0.0001 vs. WT; Fig. 2D). 
No differences in brain aromatase expression were found between genotypes (data not shown). Also in SHBG-Tg 
mice, E2 levels in the brain were strongly associated (R2 = 0.76, P = 0.02) with the average distance run per day 
(Supplementary Fig. 1). A significant correlation between the two parameters was also observed for all animals 
but not for WT group alone (Supplementary Fig. 1).
Testosterone stimulation of wheel running is independent of its action on muscle. We next 
tested if the stimulatory actions of T on wheel running activity in male mice were associated with an improve-
ment of their physical ability. At the end of the wheel running period (short-term ORX), neither ORX nor hor-
mone replacement in C57BL/6J male mice altered the percentage of lean tissue mass by DXA (Fig. 3A) or grip 
strength (Fig. 3B). Also at this stage, androgens had no effect on peripheral nerve function, as determined in 
vivo by analyzing the compound muscle action potentials (CMAPs) amplitude elicited by the stimulation of the 
sciatic nerve (Fig. 3C). When animals were kept two months post-ORX (long-term ORX), we observed an effect 
of T, and to a lesser extent of DHT, increasing lean mass (P < 0.0001 and P < 0.05 vs. ORX, respectively; Fig. 3A), 
although there was only a tendency to a better performance in the grip strength test (P = 0.076; Fig. 3B). Similarly, 
the values of lean tissue mass (Fig. 3D) and grip strength (Fig. 3E) were indistinguishable between short-term 
ORX + T-treated SHBG-Tg and WT mice, consistent with previous reports21.
To prove that myogenic AR was not driving the effects of T on wheel running, we compared wheel running 
activity of male WT and conditional satellite-cell lineage ARKO (satARKO) mice, both treated with T following 
ORX. The disruption of AR in satARKO mice is restricted to skeletal muscle27. In consistence with our previous 
results27, satARKO mice displayed normal hindlimb muscle weight but a 50% reduction in the mass of LA/BC 
(P < 0.0001 vs. WT; Supplementary Fig. 2A). Wheel running patterns were comparable between genotypes, thus 
demonstrating that myogenic AR is dispensable for wheel running in male mice (Supplementary Fig. 2B).
Figure 1. Effects of androgens on physical activity in C57BL/6J male mice. Time course of daily wheel running 
activity over a period of 19 days (A) and average distance run per day after two weeks of training (B). Note that 
the color of the stars in A represents the specific comparisons. Average distance run per day after two weeks 
of training during exposure to vehicle and treatment with increasing doses of enzalutamide (C). Ambulatory 
movement beam breaks over 23 h (D) and total cumulative ambulatory activity during the night (E). (F) 
Seminal vesicle and LA/BC weight following ORX and replacement with T or DHT. Data in panels A and C 
were analyzed using two-way repeated measures ANOVA and those in panels B and E–F were analyzed by one-
way ANOVA. Data are presented as mean ± SEM. In (A,B) and (F), n = 5–10 animals per group; in (C), n = 6 
animals per group; in (D,E), n = 10–11 animals per group. Statistical significance levels: *, **, ***, ****P < 0.05, 
0.01, 0.001 and 0.0001. ENZA enzalutamide, LA/BC levator ani/bulbocavernosus, SV seminal vesicles.
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Testosterone increases wheel running activity even in the absence of AR. Our results in ORX 
mice supplemented with T and DHT as well as in ORX + T-treated mice receiving enzalutamide suggested a dual 
role (androgenic and estrogenic) for T in the regulation of wheel running. To confirm the ability of T to stimu-
late activity in an AR-independent manner, we performed ORX and hormone replacement studies in male mice 
lacking the AR. We first ruled out the presence of other behavioral alterations in androgen receptor KO (ARKO) 
mice besides locomotion. No differences between genotypes were observed when evaluating standard measures 
of anxiety in the elevated plus maze (Supplementary Fig. 3A) nor in the test of spatial memory Morris Water 
maze (Supplementary Fig. 3B and C). We also confirmed the ability of ARKO mice to aromatize T. Following 
an acute administration of intranasal T, there was a 2.5 fold increase in brain E2 levels of ARKO mice (sham: 
2.88 ± 0.72 pg/mL; T: 7.57 ± 0.89 pg/mL; P < 0.05; Fig. 4A), which otherwise were low compared to WT.
Intact ARKO mice showed a 70% reduction in wheel running (WT: 4.44 ± 0.52 km; ARKO: 1.47 ± 0.16 km; 
P < 0.001; Fig. 4B and C) and a 24% decrease in home-cage activity (WT: 5930 ± 550 beam counts; ARKO: 
4499 ± 389 beam counts; P < 0.05; Fig. 4C and D). As expected, the low wheel running phenotype in ARKO 
mice was maintained after supplementation with DHT (Fig. 4E and F). In contrast, T replacement resulted in 
a rapid and dramatic enhancement of wheel running activity [treatment: F(3,13) = 8.763, P = 0.0019; time: 
F(18,234) = 8.497, P < 0.0001; interaction: F(54,234) = 4.124, P < 0.0001; Fig. 4E], reaching a 225% increase dur-
ing the plateau phase compared to ORX (P < 0.01 vs. ORX; Fig. 4F). The effectiveness of T supplementation was 
confirmed by higher E2 levels in brain homogenates (Fig. 4A).
The low activity phenotype in ARKO animals was not associated with any alteration in grip strength, rotarod 
test performance, peripheral nerve function or motor neuron counts in the spinal cord (Supplementary Fig. 4). 
Indeed, despite the dramatic increase in wheel running in ORX + T-treated ARKO mice, these animals showed 
an indistinguishable grip strength compared to sham and ORX + DHT groups (Fig. 4G).
Testosterone attenuates the in vivo sensitivity to amphetamine. Our results show that T pro-
motes physical activity in males independently of its peripheral action. Thus, the next step was to test the “central 
hypothesis”, namely that T is acting on brain circuitries responsible for motor movement, including the striatal 
monoaminergic systems.
Figure 2. SHBG inhibits the stimulatory effects of T on wheel running activity. Time course of daily wheel 
running activity over a period of 19 days (A), average distance run per day after two weeks of training (B), 
seminal vesicle and LA/BC weight (C) and concentration of E2 in brain homogenates (D) in SHBG-Tg and 
WT mice, both treated with T following ORX. Data in panel A were analyzed using two-way repeated measures 
ANOVA and those in panels B,D were analyzed by Student t-test. All data are mean ± SEM, 6 animals per group. 
Statistical significance levels: *, **, ***, ****P < 0.05, 0.01, 0.001 and 0.0001. LA/BC levator ani/bulbocavernosus, 
SV seminal vesicles.
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HPLC analysis revealed that neither ORX nor hormone replacement in C57BL/6J mice altered the striatal 
tissue content of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), seroto-
nin (5-HT), 5-hydroxyindolacetic acid (5-HIAA), or the metabolite/monoamine ratios (Fig. 5A–E). However, 
ARKO mice displayed lower DA striatal levels compared to WT littermates (WT: 6119 ± 451 ng/g tissue; ARKO: 
3944 ± 580 ng/g tissue; P < 0.01; Fig. 5F), a decrease associated to an enhanced DA metabolism, as indicated by 
an increased HVA/DA ratio (Fig. 5H). Also in ARKO mice, the content of 5-HT and its metabolites remained 
unaltered (Fig. 5I–J). Regardless of the experimental group, the concentrations of noradrenaline (NAD) in the 
dorsal striatum were often below the limit of detection of the HPLC method and therefore are not shown.
As previously described28, ORX had no effect on the transcript levels of DA-related genes in the striatum, as 
assessed by qPCR analysis (Fig. 5K). Still, hormone replacement increased the expression of several DA-related 
genes, reaching statistical significance for Drd2 and adenylyl cyclase type 5 (Adcy5) in ORX + T, and for both 
Drd1 and Drd2, the DA metabolic enzyme monoamine oxidase A (Maoa) and Adcy5 in ORX + DHT (Fig. 5K). 
Regarding ARKO mice, the deletion of AR reduced the mRNA levels of DA receptors, although statistical sig-
nificance was only reached for Drd1, and increased the expression of the metabolic enzymes Maoa and Maob 
(Fig. 5L).
We also evaluated if T modulated DA-sensitive behaviors in vivo. To this end, mice were challenged with an 
injection of amphetamine, which increases DA concentrations in the synapse and induces a hyperlocomotion 
response.
The evolution in the beam break counts after administration of amphetamine at a dose of 3 mg/kg was sim-
ilar between sham and ORX + placebo- or DHT-treated mice (Fig. 6A). However, ORX + T mice displayed a 
blunted response compared to the rest of the groups [interaction: F(69,851) = 1.968, P < 0,05; Fig. 6A]. Two-way 
repeated-measures ANOVA revealed a significant main effect of androgens, time as well as their interaction on 
the amount of locomotor activity following injections of 0.75 mg/kg amphetamine [androgens: F(3,37) = 4.216, 
p = 0.0116; time: F(23,851) = 46.24, p < 0.0001; interaction: F(69,851) = 1.968, p < 0.0001]. Post hoc analy-
sis revealed that ORX mice displayed a more pronounced locomotion response vs. sham animals at both 20 
and 30 min post-injection (P < 0.01 and 0,05, respectively; Fig. 6B), an effect totally prevented by T (P < 0.0001 
vs. ORX; Fig. 6B) but not DHT. As shown in the inset of Fig. 6B, the 40 min cumulative locomotor activity 
post-injection was significantly decreased in ORX + T- compared to ORX + placebo-treated mice. In a similar 
pattern, ARKO mice displayed an enhanced locomotion response to amphetamine at both 0.75 and 3 mg/kg 
(Fig. 6C and D).
Finally, we tested if T-mediated modulation of the locomotion response to amphetamine was driven by 
non-genomic rapid mechanisms, as suggested for other T-dependent behaviors29. Intranasal T increased T levels 
in both serum and brain after a few minutes (Supplementary Fig. 5A). However, short-term exposure to intrana-
sal T did not alter the hyperlocomotion response to 3 mg/kg amphetamine in ORX mice (Supplementary Fig. 5B).
Figure 3. Testosterone stimulation of wheel running is independent of its peripheral action. Percentage of lean 
mass by DEXA (A,D) and total-limb maximal grip strength (B,E) in C57BL/6J (A,B) and SHBG-Tg and WT 
mice (D,E). Mean sciatic CMAP amplitudes after ORX and replacement with T or DHT in C57BL/6 J mice (C). 
Data in panel A–C were analyzed using one-way ANOVA and those in panels D,E were analyzed by Student 
t-test. Data are presented as mean ± SEM. In A–C, n = 5–9 animals per group; in (D,E), n = 6 animals per 
group. Statistical significance levels: *, ****P < 0.05 and 0.0001. CMAP compound muscle action potential.
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Dopamine receptor antagonism selectively reduces the effects of testosterone on wheel run-
ning. To confirm the role of DA on the actions of T on wheel running, we challenged both ORX + placebo- 
and ORX + T-treated mice with DA antagonists. The addition of the DR2 antagonist haloperidol in the drinking 
water elicited a dose-dependent suppression of wheel running (Fig. 7A and D). Two-way repeated-measures 
ANOVA revealed a significant main effect of T, haloperidol dose as well as their interaction on the relative drop 
of wheel running [T: F(1,17) = 12.4, p = 0.0026; dose: F(1,17) = 19.76, P < 0.001; interaction: F(1,17) = 4.776, 
P < 0.05, Fig. 7D]. The decrease of activity in ORX + T-treated mice after two increasing doses of haloperidol was 
enhanced by 68 and 92%, respectively, compared to ORX + placebo group (Fig. 7D). Similarly, i.p. injections with 
increasing doses of the DR2 antagonist L-741,626 resulted in an inhibition of wheel running but only in ORX + 
T mice [T: F(1,10) = 15.18, P < 0.01; dose: F(3,30) = 0.59, P > 0.05; interaction: F(3,30) = 1.104, P > 0.05, Fig. 7B 
and E].
Finally, treatment with the DR1 antagonist SCH23390 exerted only a marginal reduction in the distance run, 
regardless of whether mice were receiving T replacement or placebo (Fig. 7C and F).
Figure 4. Testosterone restores wheel running activity even in the absence of AR-signaling. (A) Concentration 
of E2 in brain homogenates in WT and ARKO mice after both ORX and hormone replacement or intranasal 
treatment with T. Circadian patterns of wheel running (B) and average distance run per day (C, upper panel) 
in trained ARKO and WT mice. Ambulatory movement beam breaks over 23 h (D) and total cumulative 
ambulatory activity during the night (C, lower panel). Time course of daily wheel running activity over a 
period of 19 days (E) and average distance run per day after two weeks of training (F) in ARKO mice after 
ORX and hormone replacement. Note that the color of the stars in (E) represents the specific comparisons. 
Total-limb maximal grip strength (G) in sham, ARKO + T and ARKO + DHT mice. Data in panel A, F and G 
were analyzed using one-way ANOVA and those in panels C and E were analyzed by Student t-test and two-
way repeated measures ANOVA, respectively. Data are presented as mean ± SEM. In (A) n = 3–14 animals per 
group; in (B and C) (upper panel), n = 18 animals per group; in C (lower panel) and D, n = 17–21 animals per 
group; in (E and F), n = 3–6 animals per group; in G n = 5–8 animals per group. Statistical significance levels:  
*, **, ***, ****P < 0.05, 0.01, 0.001 and 0.0001.
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Discussion
The etiology of physical activity in humans has been suggested to be multi-factorial, involving complex interac-
tions between individual, social, and environmental elements30. Of particular interest is the role of potential bio-
logical factors determining the willingness/ motivation to engage in exercise. The effects of castration abrogating 
wheel running in rodents were already reported decades ago24. However, little progress has been made since then 
in our knowledge of how T regulates physical activity. The results of the present study clearly show the central 
nature of T actions on wheel running, whilst confirming that the contribution of muscle AR is marginal. Also, 
our findings point towards a role for T as an estrogenic prohormone in the regulation of activity. Furthermore, 
we show for the first time the regulation of wheel running via the free fraction of T, confirming the free hormone 
hypothesis for T. Finally, our results demonstrate that T-induced stimulation of wheel running is dependent on 
the DA system.
This study is the first systematic approach to address activity behavior by both wheel running and home-cage 
activity and this as well in ORX as ARKO mice. The two locomotion parameters have been often considered as 
interchangeable in rodents. However, evidence suggests that wheel running is not solely a motor response but is 
rather an incentive-motivated behavior. For instance, rats will press a lever to gain access to a running wheel31 and 
will develop preference for environments previously associated with wheel running32. Indeed, wheel running has 
been used as an animal model to study the mechanisms underlying the “runner’s high” in humans32. The motiva-
tional nature might account for the differences in the impact of androgen deficiency on wheel running and home 
cage activity. Both ORX and ARKO mice showed a reduction in the two locomotion parameters but the decrease 
was far more pronounced in wheel running. In contrast to previous studies6,7, the post-ORX recovery period in 
this study was minimal (48 h) and the early pre-plateau phases were also included in the analysis. We hereby were 
able to show that several wheel running parameters were already altered within the first week after castration. This 
rapid and dramatic action of ORX places physical activity as a highly androgen-sensitive parameter in male mice, 
similar even to classical androgen-responsive reproductive organs.
Figure 5. Effects of androgens on the striatal monoaminergic system. DA (A,F), DOPAC to DA ratio 
(B,G), HVA to DA ratio (C,H), 5-HT (D,I) and 5-HIAA to 5-HT ratio (E,J) were measured by HPLC in the 
dorsal striatum of C57BL/6J (A–E) and ARKO and WT mice (F–J). Quantitative real-time PCR analysis of 
striatal mRNA levels of dopamine receptor 1 (Drd1) and 2 (Drd2), postsynaptic density protein 95 (Dlg4), 
neurofilament, medium polypeptide (Nefm), monoamine oxidase A (Maoa) and B (Maob), catechol-O-
methyltransferase (Comt), adenylate cyclase (Adcy5) and olfactory isoform of the stimulatory GTP-binding 
protein alpha subunit (Gnal) of C57BL/6J (K) and ARKO and WT mice (L). Data in panels A–E and K were 
analyzed using one-way ANOVA and those in panels F–J and L were analyzed by Student t-test. Data are 
presented as mean ± SEM. In (A–E), n = 7–9 animals per group; in F–J, n = 10 animals per group; in K, n = 6–9 
animals per group; in L, n = 7 animals per group. Statistical significance levels: *, **P < 0.05 and 0.01. 5-HT 
serotonin, 5-HIAA hydroxyindolacetic acid, DA dopamine, DOPAC 3,4-dihydroxyphenylacetic acid, HVA 
homovanillic acid.
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Compared to total T concentrations, free levels of T are a better predictor of deficiency–related symptoms in 
elderly men with late-onset hypogonadism10. The impact of the free fraction of T on wheel running was investi-
gated by using SHBG-Tg mice20. This approach also allowed us to compare the results of ORX and ARKO mice 
to a less “complete” androgen deficiency model. When provided with an equal amount of T, SHBG-Tg mice 
display a decrease in the free levels of T due to SHBG binding21. Under these circumstances, SHBG-Tg mice 
showed a low wheel running phenotype associated to a reduced systemic androgen bioactivity, as evidenced by 
seminal vesicle weight. In addition, their brain levels of E2 were diminished despite a similar expression of brain 
aromatase vs. WT, thereby indicating a reduced availability of substrate T to enter the brain from the circulation 
and become locally aromatized into E2, which is in line with our previous observations21. The decline of total T 
in ageing is only moderate whereas the rise in SHBG concentrations and decline in free T are more pronounced9. 
Therefore, SHBG-Tg mice may be a more suitable animal model to study late-onset hypogonadism than ORX. 
Despite the obvious limitations of comparing data across different models, it is remarkable that SHBG-Tg mice 
still run slightly more than ORX mice. Therefore, the T-induced boosting of wheel running in male mice might 
be fine-tuned by a concentration-response pattern. In accordance, we observed a significant association between 
wheel running and E2 levels in the brain, particularly at low concentrations (SHBG-Tg mice). However, further 
studies using different T concentrations are warranted to corroborate this hypothesis.
Many of the actions of T in male behavior are mediated by ERs22. In male mice, the circulating levels of E2 are 
negligible21 while aromatase is highly expressed in the brain, suggesting a role for the autocrine and paracrine 
actions of estrogens33. Regarding wheel running, the extent to which AR and ERs contribute to the T-induced 
stimulation of activity remains unclear. In ORX rats, wheel running was unaffected by the non-aromatizable DHT 
while it dramatically increased after treatment with E224. Still, treating male rats with systemic E2 is a rather poor 
physiological approach since their serum E2 concentrations are extremely low34. More recent studies in mice6,7 
showed a moderate but consistent effect of DHT in rescuing wheel running after castration. In accordance, our 
experiments with both DHT and enzalutamide indicated that AR-signaling stimulates wheel running in male 
mice, yet still not sufficient to explain the full action of T. DHT can be metabolized in vivo to 3α-diol and 3β-diol, 
which display a weak AR binding activity and act through the gamma-aminobutyric acid (GABA) type A and/
or ERs to initiate biological responses35,36. We proved here that the weak actions of DHT on wheel running were 
mediated through AR mechanisms since these were no longer observed in ARKO mice. We next challenged 
ARKO mice with T to determine the implication of AR-independent mechanisms. This approach was chosen 
Figure 6. Androgen deficiency aggravates and treatment with T attenuates the locomotion response to 
amphetamine. Time course of locomotor-induced behavior after i.p. injection with 3 (A,C) or 0.75 mg/kg 
(B,D) amphetamine in C57BL/6 J (A,B) and ARKO and WT mice (C,D). The inset graphs show the cumulative 
beam breaks during 40 min. Locomotor activity evolution was analyzed using two-way repeated measures 
ANOVA. Cumulative activities were analyzed using one-way ANOVA or Student t-test. Data are presented 
as mean ± SEM. In (A,B), n = 10–11 animals per group; in (C,D), n = 7–8 animals per group. Statistical 
significance levels: *, **P < 0.05 and 0.01 vs. WT. #P < 0.05 vs. sham and ORX T. $P < 0.05 vs. ORX T.
www.nature.com/scientificreports/
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over systemic treatment with E2 since circulating E2 is unphysiological in mice, while T treatment in ARKO mice 
better replicates the suggested local nature of the estrogenic action in male mice21,33. Even in the absence of AR, 
treatment with T increased wheel running in mice, an effect that was associated with an up-regulation of brain E2 
levels. Although we cannot fully exclude the possibility that T actions on global ARKO mice imply other mecha-
nisms outside ERs pathways, this seems unlikely since the non-aromatizable androgen DHT did not recapitulate 
T effects. Therefore, our results point to a full action of T on wheel running dependent on prior aromatization 
into E2.
The modulation of wheel running in male mice by androgens could be reflective of changes in their overall 
physical ability. Our results did not indicate an impaired neuromuscular function in any of the 3 mouse models of 
androgen deficiency. Still, we cannot rule out potential alterations in the intrinsic contractile properties of skeletal 
muscle since we did not include a “pure” readout of muscle strength. Both ORX37 and AR deletion38 result in a 
mild reduction in the mass as well as the in vitro contractility of hindlimb muscles. However, this is not trans-
lated into an alteration of the in vivo endurance capacity17,39. Thus, it seems unlikely that the beneficial effects of 
androgens on muscle intrinsic properties could explain the stimulatory actions of T on wheel running activity. 
Supporting our view, satARKO and control mice displayed comparable levels of wheel running, demonstrating 
that myogenic AR is dispensable for wheel running in male mice.
We next tested the “central hypothesis”, namely that T mainly was acting on brain circuitries to stimulate 
wheel running. Voluntary exercise is likely regulated by a complex network of neuromediators but the DA sys-
tem has been suggested as the final common pathway. Both optogenetics25 and designer receptors exclusively 
activated by designer drugs (DREADD)40 studies corroborate the activation of DR1- and DR2-neurons in the 
striatum as a key determinant for locomotion. Castration and T replacement in male rodents have been asso-
ciated to changes in DA synthesis, transport, release, metabolization and/or signaling, despite the direction of 
the changes varies depending on the brain region and time post-castration assessed26. In humans, PET studies 
suggest the existence of sex differences in DA function41. We chose to explore the dorsal striatum based on pre-
vious findings showing that the alterations in the DA system associated to wheel running hyperactivity are more 
pronounced in this region than in the nucleus accumbens42. Accumulated data reveal a previously neglected role 
for the nigrostriatal pathway facilitating motivational behaviors43. Here, we show a substantial loss of DA in the 
striatum of ARKO mice, associated with an increased metabolism ratio. Also in ARKO, there was a reduction 
in the striatal expression of DA receptors while the mRNA levels of the metabolic enzymes Maoa and Maob 
were up-regulated. Therefore, a diminished DA tone could be the neural basis underpinning the low locomotion 
Figure 7. DR2 antagonism inhibits T-induced stimulation of wheel running. Running-wheel activity during 
baseline (first three days) and after treatment with increasing doses of haloperidol (A), L-741,626 (B) and 
SCH23390 (C). Percentage of reduction from baseline after exposure to haloperidol (D), L-741,626 (E) and 
SCH23390 (F). Data in panels D–F were analyzed using two-way repeated measures ANOVA. Data are 
presented as mean ± SEM. In (A and D), n = 8–11 animals per group; in B and E, n = 6 animals per group; in  
(C and F), n = 4–6 animals per group. Statistical significance levels: *, **, ***P < 0.05, 0.01 and 0.001.
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phenotype of ARKO mice. Unexpectedly, ORX per se however had no effects either on DA concentrations or on 
DA-related genes in the striatum, despite the fact that both T and DHT enhanced the transcript levels of Drd2 
and Adcy5. A similar pattern after ORX and hormone replacement was reported in a recent study in adolescent 
rats28. Since we show that changes in wheel running occurred very early after ORX, it is possible that we have 
“missed” early androgen-regulated changes in gene expression. Another possibility is that T acts primarily on 
the DA system by regulating the availability of extracellular DA44–46. Remarkably, ORX not only influences the 
basal concentrations of extracellular DA but also its release upon stimulation46. We hypothesize that ORX mice 
display a hypo-dopaminergic state and that treatment with T rescues their wheel running activity by restoring the 
basal dopaminergic tone. In contrast, T might restrain the enhanced release of DA in target brain regions of ORX 
animals after amphetamine challenge, thus attenuating the resultant locomotor response. Our results indicate 
that T restores the sensitivity to amphetamine in male mice through ERs-dependent mechanisms, since DHT 
was ineffective. These findings are supported by a recent study in rats showing similar actions for ORX and T after 
amphetamine challenge47.
Androgens are known to exert quick-acting effects on male behavior29,48. Intranasal administration is particu-
larly effective in delivering T to the brain in mice49. However, in our conditions, a short-exposure to intranasal 
T did not attenuate the hyperlocomotion response in ORX mice after amphetamine challenge. Thus, the results 
do not support a role for T acting on the DA system through either non-genomic or rapid genomic mechanisms.
Finally, we tested if the selective antagonism of DA receptors could significantly prevent the wheel running 
induced by T. Addition of low doses of the DR2 antagonist haloperidol to the drinking water induced a reduction 
in wheel running that was far more pronounced in ORX + T- than ORX + placebo-treated mice. In a similar pat-
tern, treatment with the DR2 antagonist L-741,626 reduced by almost 50% the distance ran by ORX + T-treated 
mice. This 741,626 regimen however was not effective decreasing wheel running in ORX + placebo-treated ani-
mals or in Balb/cJ female mice50. Therefore, it is unlikely that the doses of 741,626 used here altered per se the 
physical ability of mice to run in the wheel. We conclude that DR2-dependent pathways are implicated in the 
T-induced stimulation of wheel running.
As discussed above, a limitation of our study is that we could not identify the precise mechanisms through 
which T modulates the DA system to increase wheel running. In addition, due to the complexity of the biology of 
DA receptors interactions, we cannot rule out the contribution of DR1, despite the doses of oral SCH23390 used 
here exerted biological effects in vivo50. Finally, other neurotransmitter systems, like those involved in energy reg-
ulation, are likely involved in additionally mediating the neuroendocrine effects of T on wheel running behavior.
In summary, our study reveals that T deficiency impairs physical activity in male mice manifestly, and that this 
effect is a purely central phenomenon and not the result of a muscle dysfunction. We also provide a novel illus-
tration that free T acts as prohormone for E2 in the brain to regulate wheel running via DA-dependent pathways. 
Clinically, the impact of T actions on physical activity could represent an additional benefit of T replacement 
therapy in ageing men with sarcopenia, dysmobility and low T.
Methods
Mice. Male C57BL/6J mice were obtained from the KU Leuven animal facility, prior confirmation of genetic 
background purity by JAX SNP panels. Generation of male C57BL/6J mice with a ubiquitous knockout of the 
androgen receptor (ARKO) has been previously described51. Male ARKO mice display a complete androgen 
insensitivity syndrome with smaller gonads located in the abdominal region51. Heterozygous SHBG(4.3kb)+/− 
mice were a generous gift from prof. GL. Hammond (University of British Columbia, Vancouver, B.C, Canada). 
Male mice heterozygous for a cyclization recombinase driven by the MyoD-iCre (generously donated by dr. D. 
Goldhamer, University of Connecticut, Storss, CT, USA) were bred with female mice heterozygous for a floxed 
AR exon 2 allele to generate male conditional satellite-cell lineage ARKO (satARKO, ARflox/YCre+/−) and male 
control (pool of ARwt/YCre−/−, ARflox/YCre−/− and ARwt/YCre+/− genotypes) mice, as described27.
Mice were group-housed at 20 °C with a 12h-dark/light cycle with ad libitum access to food and water, accord-
ing to our institutional guidelines. For ex vivo analyses, animals were euthanized by pentobarbital anesthesia 
followed by cardiac puncture. Tissues were dissected and wet weight measured.
Surgical procedures. At 16 weeks of age, both male C57BL/6J and ARKO mice and their male wild type 
(WT) littermates underwent ORX (abdominal approach) under isoflurane anaesthesia followed by buprenor-
phine analgesia (60 µg/kg SC). Implants of medical-grade silicone tubing (Silclear®, Degania Medical, Degania, 
Israel) sealed with medical adhesive silicone (Silastic®, Biesterfeld, Germany) were implanted in the nuchal 
region, either empty or filled with T or DHT (both from Sigma-Aldrich, St. Louis, MO, USA). The same surgical 
procedure except for the removal of the testis or gonads was conducted in sham animals, which received an empty 
implant. Also at 16 weeks of age, both male SHBG-Tg and satARKO mice and their respective male WT litter-
mates were ORX and replaced with a T implant. Under these conditions, we have previously demonstrated that 
male SHBG-Tg mice display a mild hypogonadism phenotype, characterized by a decrease in free T serum levels 
and a reduction in the weights of seminal vesicles and levator ani/bulbocavernosus (LA/BC) muscle complex21.
Wheel running. Following 2 days of post-surgery recovery, animals were introduced into individual cages 
equipped with computerized running wheels (Linton Instrumentation Inc., Diss, Norfolk, UK). Revolutions were 
measured electronically in 10-min bins of activity for 19 days and afterwards the running distance was calculated.
Treatment with dopamine antagonists. Haloperidol (Haldol®, Janssen-Cilag, Berchem, Belgium) and 
SCH23390 (Tocris Bioscience, Ellisville, MO, USA) were dissolved in distilled water and then administered in 
the drinking water at doses of 0, 0.15 and 0.30, and 0, 0.05 and 0.1 mg/kg-day, respectively. The concentrations of 
haloperidol and SCH23390 were calculated taking into account the average daily water consumption and weight 
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of mice. Bottles were wrapped in aluminum foil and the drugged water was renewed on a daily basis. Prior to 
drug exposure, wheel running at the plateau phase was recorded for three consecutive days and taken as baseline. 
L-741,626 (Tocris Bioscience) was first dissolved in ethanol and then diluted with distilled water (final ethanol 
concentration 6%). The animals were accustomed to handling and i.p. injections with vehicle for 7 days before 
exposure to L-741,626 (1, 2, 5 and 10 mg/kg). The last three days of the habituation period were used as baseline.
Treatment with enzalutamide. Enzalutamide (Sequoia Research Products, Pangbourne, United 
Kingdom) was prepared in 1% carboxymethyl cellulose, 0.5% Tween 80, and 5% dimethylsulfoxide52. Wheel run-
ning was recorded for three days during which animals were treated daily with vehicle, and then 3 days per dose 
of enzalutamide (30 and 60 mg/Kg, p.o.).
Home-cage activity. A new group of animals with non-access to a wheel was used, as to avoid the con-
founding effects of previous running53. Mice were housed individually in 20 × 30 cm2 transparent cages located 
between three photo beams and activity was measured as beam crossings for each 30 min, during a 23 h interval.
Locomotion response to amphetamine. Following a 180-min habituation period in the activity cage, 
mice received an i.p. injection of vehicle (saline, 10 mL/Kg) and were monitored for another 60 min. Afterwards, 
the procedure was repeated but, instead of saline, animals were challenged with amphetamine (3 mg/kg; Tocris 
Bioscience). The hyperlocomotion response to the drug was recorded for 180 min. After a three week wash-out 
period, the experiment was repeated with a lower dose of amphetamine (0.75 mg/kg).
In another set of experiments, ORX + placebo-treated mice were subjected to the former procedure but, 
prior to the challenge with 3 mg/kg amphetamine, they received either intranasal T (2 mg/kg, 12 µL per mouse) 
or vehicle (sesame oil). A subgroup of animals was euthanized 25 min after T or vehicle administration and the 
levels of T in serum and brain extracts were determined by liquid chromatography tandem mass spectrometry 
(LC-MS/MS).
Elevated plus maze. The apparatus consisted of an elevated (30 cm) maze with two closed (21 cm 
long × 5 cm wide) and two open arms making the shape of a cross. Mice were placed at the center of the maze and 
were allowed to move freely for 10 min. The number of arm entries was recorded by four infrared beams.
Morris-type water maze. The test included two probe trials, in which the hidden platform was removed 
from the pool, after each five days of training. The learning curves (using swim path length to reach the hidden 
platform) were determined over 10 days of training. For the probe trials, the time spent in each quadrant was 
calculated.
Grip strength. Total-limb maximal grip strength was evaluated by means of a grid connected to an isometric 
force transducer (Chatillon DFIS-2 Digital Force Gauche, Ametek, Paoli, PA, USA). Mice grasping a metal grip 
with all limbs were pulled horizontally by their tails until they lost their grip. Measurements were registered in 
Newtons (N) and the result was set as the average of six attempts.
Rotarod test. General motor performance was assessed using an accelerating rotarod (Ugo Basile, Comerio, 
Italy) rotating from 4 to 40 rpm on 5 min ramp duration. Each mouse was subjected to six sessions without prior 
training and the latency to fall was recorded for each trial.
Neuron counts. Paraformaldehyde-fixed lumbosacral spinal cord tissue samples were processed routinely 
for paraffin embedding, and 20-μm sections were obtained for Nissl staining. All images were acquired and ana-
lyzed using a Zeiss Axiovert microscope. Cresyl violet positive neurons located in the ventral horn, with a soma 
area over 250 μm2 and a clearly defined nucleus were included in the counts.
Electrophysiology. Mice were anaesthetized under a 2.5% oxygen flow containing 1.5–2% isoflurane. 
Nerve conduction studies were performed using sub-dermal needle electrodes (Technomed Europe, Maastricht, 
Netherlands) and a Natus UltraPro S100 (Natus Medical Incorporated, San Carlos, CA, USA). Compound muscle 
action potentials (CMAPs), were determined by measuring the response at the gastrocnemius muscle after stim-
ulation occurred at the level of the sciatic notch.
DXA. Lean and fat mass were analyzed in vivo using the PIXImus mouse densitometer (Lunar Corp) with an 
ultrahigh resolution (0.18 × 0.18 pixels, 1.6 line pairs/mm) and software version 1.45.
Liquid chromatography- tandem mass spectrometry. Sex steroid concentrations were measured 
using LC-MS/MS. Prior to LC-MS/MS analysis, brain tissues were homogenized and extracted with diethyl ether, 
as previously described54. Total T and E2 in both serum and brain tissue extracts were measured at the University 
Hospitals Leuven by LC-MS/MS without derivatization using a two-dimensional chromatography system and 
an AB/Sciex QTrap 5500 tandem mass spectrometer in atmospheric pressure chemical ionization positive and 
electrospray ionization negative ion mode, respectively.
Analysis of the total monoamine/metabolite content. The total noradrenaline (NAD), dopamine 
(DA) and serotonin (5-HT) content as well as their metabolites 3,4-dihydroxyphenylacetic acid (DOPAC), 
homovanillic acid (HVA) and 5-hydroxyindolacetic acid (5-HIAA) in the striatum were measured based on 
previously reported methods55. In summary, after weighing striatal tissue, 190 µL of an antioxidant solution 
(0.1 M acetic acid, 3.3 mM L-cysteine, 0.27 mM Na2EDTA and 0.0125 mM ascorbic acid) and 10 µL of an internal 
standard solution (3,4-dihydroxybenzylamine solution 1 µg/mL in antioxidant) were added to the tissue. After 
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homogenization, the samples were centrifuged (20 min, 9500 g, 4 °C). The supernatant was diluted 5-fold in 0.5 M 
acetic acid and 20 µL was injected automatically on a reversed phase liquid chromatography system (autosampler 
ASI-100 and HPLC pump P680 A HPG/2, Dionex, Amsterdam, The Netherlands) with electrochemical detection 
(potential = +700 mV) (Amperometric Detector LC-4C, BAS). The separation was achieved using a narrowbore 
C18 column (Alltech®, AlltimaTM, 5 µm, 150 × 2.1 mm, Grace, Deerfield, IL, USA). The mobile phase buffer 
contained 0.1 M sodium acetate, 20 mM citric acid, 1 mM sodium octane sulfonic acid, 1 mM dibutylamine and 
0.1 mM Na2EDTA adjusted to pH 3.7 (mobile phase composition: 97 buffer/3 methanol (v/v)). Tissue concentra-
tion was expressed as ng monoamine (or metabolite)/g wet tissue (ng/g).
Quantitative PCR. Total RNA was extracted from tissue samples by homogenization in Trizol reagent 
(Invitrogen, Carlsbad, CA, USA) followed by isopropanol precipitation. For cDNA synthesis, a superscript II 
RNaseH– reverse transcriptase kit was used (Invitrogen). The primer sequences are described in Table 1. The 
PCR mixtures (10 µl) contained 5 µl Fast SYBR green Master Mix (Applied Biosystems, Foster City, CA, USA) and 
0.03 µM of each primer. For quantification of gene expression, the StepOnePlus™ sequence detector PCR detec-
tion system (Applied Biosystems) was used. The housekeeping gene hypoxanthine guanine phosphoribosyl trans-
ferase (Hprt) served as an endogenous control and expression levels were analyzed by the 2−ΔΔCT method.
Statistics. Statistical analysis was performed using Graphpad Prism v6.05. Student t-test and one- way 
ANOVA followed by Bonferroni’s post-hoc test were used to analyze differences between two groups or more, 
respectively. When two independent variables were included in the analysis, two-way ANOVA was performed. 
Evolution of groups over time was analyzed with repeated measures ANOVA. All statistical tests were performed 
two-tailed. Data are expressed as mean ± SEM and P values < 0.05 were considered statistically significant.
Study approval. All experiments involving animals were performed in accordance with relevant guidelines 
and regulations and were conducted with approval of the KU Leuven ethical committee (P041/2014).
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